Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

Publication Type:

Journal Article

Authors:

Bartlett, Nancy L; Chen, Robert; Fanale, Michelle A; Brice, Pauline; Gopal, Ajay; Smith, Scott E; Advani, Ranjana; Matous, Jeffrey V; Ramchandren, Radhakrishnan; Rosenblatt, Joseph D; Huebner, Dirk; Levine, Pamela; Grove, Laurie; Forero-Torres, Andres

Source:

Journal of hematology & oncology, Volume 7, Issue 1, p.24 (2014)

Keywords:

2014, April 2014, Clinical Research Division

Abstract:

Brentuximab vedotin is a CD30-directed antibody-drug conjugate. Retreatment with brentuximab vedotin monotherapy was investigated in patients with CD30-positive Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (ALCL) who relapsed after achieving complete or partial remission (CR or PR) with initial brentuximab vedotin therapy in a previous study (ClinicalTrials.gov NCT00947856).